Rockville, MD, USA, November 17, 2020
ReveraGen, Inc., a privately held company developing vamorolone (VBP15) as a potential safer alternative for corticosteroid treatment in Duchenne muscular dystrophy and other disorders, today announced an award of a $3.3 million grant
Pratteln, Switzerland, and Rockville, MD, USA, September 22, 2020
Santhera Pharmaceuticals (SIX: SANN) announces that partner ReveraGen Biopharma Inc. and their academic collaborators have published new open-label, long-term clinical data
Pratteln, Switzerland, and Rockville, MD, USA, September 14, 2020
Santhera Pharmaceuticals (SIX: SANN) announces that Emory University scientists and partner ReveraGen Biopharma Inc. have published new data on the molecular mode of action of vamorolone compared to standard corticosteroids
Pratteln, Switzerland, and Rockville, MD, USA, September 11, 2020
Santhera Pharmaceuticals (SIX: SANN) announces that partner ReveraGen Biopharma Inc. has completed enrollment into the pivotal VISION-DMD study with vamorolone in patients with Duchenne muscular dystrophy (DMD).
Pratteln, Switzerland, and Rockville, MD, USA, September 2, 2020
Santhera Pharmaceuticals (SIX: SANN) announces that it has signed agreements with Idorsia (SIX: IDIA) and ReveraGen BioPharma Inc., making Santhera a direct license holder of vamorolone.
Rockville MD, 11 June 2020
Jesse’s Journey, Canada’s leader in Duchenne muscular dystrophy funded research, is proud to announce a $1M grant towards a clinical trial evaluating vamorolone for the first time in
Rockville MD, 2 June 2020
Vamorolone is a first-in-class daily oral drug being developed to improve muscle function in Duchenne muscular dystrophy. Vamorolone has multiple mechanisms of action shown by published pre-clinical studies, including potent anti-inflammatory